Резултати
еНаука >
Резултати >
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
| Title: | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). | Authors: | Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 20) | Issue Date: | 2020 | Publication: | JOURNAL OF CLINICAL ONCOLOGY | ISSN: | 0732-183X Journal of Clinical Oncology Search Idenfier |
Type: | Conference Paper | Collation: | vol. 38 br. 15 | WoS-ID: | 000560368303408 | URI: | https://enauka.gov.rs/handle/123456789/797180 | Project: | Genentech, Inc.Roche HoldingGenentech | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
198
WEB OF SCIENCETM
Google ScholarTM
Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.